Archived documents
Documents past their public comment period for Product Safety & Recalls.
Request for Information: Consumer Product Recall Fraud
20 comments
Net support +95% across analyzed comments
Top issues in comments
- Recall fraud mitigation
- Image and data authenticity
- Automatic product registration technology
Compliance Policy Regarding Premarket and Other Requirements for Certain NIOSH Approved Air-Purifying Respirators; Draft Guidance for Industry and Food and Drug Administration Staff
7 comments
Net support +100% across analyzed comments
Top issues in comments
- Regulatory oversight and clarity
- Clarify intended audience
- Occupational safety and heat stress
Color Additive Petition submitted seeking amended color additive regulations to remove FDA's approval of three carcinogenic solvents
1 comment
Net support +100% across analyzed comments
Top issues in comments
Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Testing Communications On Medical Devices and Radiation-Emitting Products
1 comment
Net support +100% across analyzed comments
Top issues in comments
Safety Standard: Toddler Beds
1 comment
Net support +100% across analyzed comments
Top issues in comments
- Chemical safety in imports
Petition: Modification of Application of Existing Mandatory Safety Standards
1 comment · 1 awaiting analysis
Analysis in progress
Top issues in comments
Agency Information Collection Activities; Proposals, Submissions, and Approvals: Safety Standard for Adult Portable Bed Rails
0 comments
Analysis in progress
Top issues in comments
Hearings, Meetings, Proceedings, etc.: National Roundtable on Childhood Drowning Prevention
0 comments
Analysis in progress
Top issues in comments
Determination That DIAZEPAM Injection United States Pharmacopeia (5 Milligrams/Milliliter in a 1- Milliliter Container) Was not Withdrawn From Sale for Reasons of Safety or Effectiveness
0 comments
Analysis in progress
Top issues in comments
Determination That PYRIDOSTIGMINE BROMIDE Tablets, 30 Milligrams, Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness
0 comments
Analysis in progress
Top issues in comments
Letter from FDA CDER to Lachman Consultant Services, Inc.
0 comments
Analysis in progress
Top issues in comments
Petition: Modification of Application of Existing Mandatory Safety Standards
0 comments
Analysis in progress
Top issues in comments